Valuation: Glenmark Pharmaceuticals Limited

Market Cap 622B 6.43B 5.65B 5.25B 4.83B 9.06B 9.22B 62.78B 24.49B 304B 24.12B 23.6B 1,053B P/E 2026
44.2x
P/E 2027 * 26.5x
Enterprise Value 583B 6.02B 5.29B 4.92B 4.52B 8.48B 8.64B 58.82B 22.94B 284B 22.6B 22.11B 987B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.51x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day+0.24%
1 week-4.02%
Current month+0.04%
1 month+0.60%
3 months-1.56%
6 months+10.41%
Current year+8.35%
1 week 2,166
Extreme 2166
2,287.9
1 month 2,142.8
Extreme 2142.8
2,326.1
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 722.1
Extreme 722.1
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-4.02%+2.19%+192.78% 6.43B
+0.57%+0.13%+16.45%+78.10% 48.31B
-0.50%-0.41%+67.13%+107.90% 35.33B
-1.56%-3.13%-4.88%+32.80% 11.85B
-1.11%-3.73%+16.41%+81.64% 11.64B
-0.84%-0.19%+36.48%+136.73% 8.99B
-0.27%+0.42%+51.66%-6.22% 6.93B
-0.77%-3.00%+13.55%+32.01% 6.72B
+1.60%-9.55%-30.77%+8.47% 5.66B
-0.55%-0.41%+25.54%+143.67% 4.48B
Average -0.30%-1.55%+19.38%+80.79% 14.64B
Weighted average by Cap. -0.18%-0.90%+27.54%+83.75%

Financials

2026 2027 *
Net sales 153B 1.58B 1.39B 1.29B 1.19B 2.23B 2.27B 15.45B 6.03B 74.68B 5.94B 5.81B 259B 167B 1.72B 1.51B 1.41B 1.29B 2.43B 2.47B 16.82B 6.56B 81.32B 6.46B 6.32B 282B
Net income 20.53B 212M 186M 173M 159M 299M 304M 2.07B 808M 10.01B 796M 779M 34.74B 23.28B 240M 211M 196M 181M 339M 345M 2.35B 916M 11.36B 903M 883M 39.4B
Net Debt -39.29B -406M -357M -332M -305M -572M -582M -3.96B -1.55B -19.17B -1.52B -1.49B -66.49B -37.12B -383M -337M -313M -288M -540M -550M -3.75B -1.46B -18.11B -1.44B -1.41B -62.82B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
23/07/26 2,205.10 +0.24% 567,718
22/07/26 ₹2,199.90 -1.88% 942,175
21/07/26 ₹2,242.10 +0.12% 274,753
20/07/26 ₹2,239.50 +0.18% 914,679
17/07/26 ₹2,235.50 -2.25% 355,968
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,205.10INR
Average target price
2,497.27INR
Spread / Average Target
+13.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock